drugset / Trial / NCT01911728
Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates
Non-randomizedCrossoverOpen-labelTreatment
Summary
A drug-drug interaction study to investigate the potential pharmacokinetic interaction between MDV3100 and a cocktail of substrates for pioglitazone (CYP2C8 substrate), S-warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A4 substrate).
Timeline
- Start
- 2011-07-25
- Primary completion
- 2012-02-21
- Completion
- 2012-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | Midazolam | Small molecule | 2 mg | Oral |
| Subject | Omeprazole | Other / unclassified | 20 mg | Oral |
| Subject | Pioglitazone | Small molecule | 30 mg | Oral |
| Subject | Warfarin | Small molecule | 10 mg | Oral |